Dynavax Technologies (DVAX) | Stock Overview & Key Data
Dynavax Technologies Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $106.60 on November 27, 2006
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dynavax Technologies
DVAX
|
1.82B Small-cap | 0.13% | -1.15% | 40.40% | 47.90% | 0.78% | 20.90% | 39.64% | 53.92% | -21.40% | -49.68% | -74.59% |
|
Zoetis
ZTS
|
49.75B Large-cap | -4.46% | -31.75% | -39.76% | -38.95% | -38.30% | -53.93% | -54.80% | -55.66% | 62.09% | 150.53% | 150.53% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | -5.84% | -5.84% | -19.96% | -10.03% | -13.00% | -20.18% | 9.16% | 22.27% | 22.27% | 22.27% | 22.27% |
|
BioCryst
BCRX
|
2.20B Mid-cap | -1.53% | -9.35% | -3.36% | 16.48% | 11.20% | -17.12% | 6.71% | -45.30% | 147.50% | 165.97% | -33.36% |
|
Perrigo Company plc
PRGO
|
1.61B Small-cap | -3.15% | -8.17% | -15.24% | -23.14% | -24.69% | -58.72% | -66.51% | -76.52% | -88.64% | -86.89% | -34.38% |
|
Ani Pharmaceuticals
ANIP
|
1.78B Small-cap | -8.30% | -9.32% | -0.76% | -9.10% | -4.82% | 33.70% | 63.56% | 128.36% | 43.87% | -27.55% | -28.50% |
Ownership & Short Interest
Calculate Your Dynavax Technologies Investment Returns
Long-Term Investment Performance Analysis
Dynavax Technologies stock price in May 2016 was $16.24, A $1,000.00 lump sum investment in Dynavax Technologies made 9 years ago would be worth approximately $954.43 today, representing a negative return of -4.56%. This translates to an annualized return (CAGR) of -0.48%.
9 Years 8 Months Investment Scenario (May 2016 - Feb 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is DVAX's 52-week high and low?
- In the last 52 weeks, Dynavax Technologies reached a high of $15.73 (on January 12, 2026) and a low of $9.20 (on September 15, 2025).
- What is the market cap and P/E ratio for DVAX?
- Curious about Dynavax Technologies's size and valuation? Its market capitalization stands at 1.82B. When it comes to valuation, the P/E ratio (trailing twelve months) is 54.60, and the forward P/E (looking ahead) is 46.97.
- Does DVAX pay dividends? If so, what's the yield?
- As for dividends, Dynavax Technologies isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Dynavax Technologies's main competitors or similar companies to consider before investing?
When looking at Dynavax Technologies, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -53.93% -54.80% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -20.18% 9.16% BioCryst
BCRX2.20B Healthcare Drug Manufacturers - Specialty & Generic -17.12% 6.71% Perrigo Company plc
PRGO1.61B Healthcare Drug Manufacturers - Specialty & Generic -58.72% -66.51% Ani Pharmaceuticals
ANIP1.78B Healthcare Drug Manufacturers - Specialty & Generic 33.70% 63.56% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dynavax Technologies Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Dynavax Technologies's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -7.14%, the Debt to Equity ratio from the most recent quarter is 54.15, and its Gross Profit Margin stands at 84.82%.
- What is the recent revenue and earnings growth for DVAX?
- Looking at Dynavax Technologies's growth, its revenue over the trailing twelve months (TTM) was $331M. Compared to the same quarter last year (YoY), quarterly revenue grew by 17.70%, and quarterly earnings saw a YoY growth of 53.00%.
- How much of DVAX stock is held by insiders and institutions?
- Wondering who owns Dynavax Technologies stock? Company insiders (like executives and directors) hold about 0.75% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 101.55%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.